A BETTER TREATMENT FOR OPIOID INDUCED RESPIRATORY DEPRESSION (OIRD)
Restoring Breathing – Preserving Pain Relief
Introduction
Unmet Need: Every year, millions of US surgical patients experience opioid-induced respiratory depression (OIRD) severe enough to require prolonged mechanical ventilation and longer hospital stays.
- Problem: Current drug for OIRD, Naloxone, restores breathing but is used infrequently because it reverses pain relief
- Solution: New drug, ATLX-0199 (sometimes referred to as Sudaxine), reverses OIRD while preserving pain relief
- Market: Over $13 billion annually
- Technology: Proprietary small molecule platform; strong animal data; NIH-backed, including SBIR grant.
- Team: Experienced, industry-known, motivated, committed
- Stage: Late pre-clinical.
Opioid-Induced Respiratory Depression
Opioid-induced respiratory depression (OIRD) is a common and potentially deadly side effect of opioids. The overall community problem affects tens of millions; in the hospital surgical setting alone it affects over 1.9 million patients annually.
In the Community
In the last decade, millions of people have died from OIRD caused by opioid overdose
In the Hospital
Opioids are often used for post-surgery pain relief, causing frequent OIRD
In the Field
U.S health officials are increasingly concerned about OIRD in terrorism
Discovering Our Lead Compound
Based on overall chemical stability, efficacy, negligible cardiovascular effects, and onset profiles, ATLX-0199 (D-Cystine diME) was selected as the lead compound for clinical development, with back-up compounds available. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.
Available Data
In-vitro & in-vivo data show compelling pre-clinical proof of concept
ATLX-0199 increases minute ventilation and overcomes opioid-induced respiratory depression. ATLX-0199 (D-Cystine diME) reverses the respiratory depression and V/Q mismatch after 10 mg/kg IV morphine in conscious rats. ATLX-0199 (D-Cystine diME) does not negatively impact the analgesic actions of morphine in freely-moving rats.
David Kalergis, JD/MBA
Stephen Lewis,
PhD
James Bates, MD/
PhD
Benjamin Gaston,
MD
Get In Touch
- 315 694 1111
- Info@atelerixlifesciences.com
-
Atelerix Life Sciences Inc.
31800 N Capitol Ave Noyes Pavilion, 5th Floor, Suite E504-ATLX Indianapolis, IN 46202